Press release
Axillary Hyperhidrosis Pipeline Appears Robust With 3+ Key Pharma Companies Actively Working in the Therapeutics Segment
In the Axillary Hyperhidrosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Axillary Hyperhidrosis clinical trials studies, Axillary Hyperhidrosis NDA approvals (if any), and product development activities comprising the technology, Axillary Hyperhidrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Axillary Hyperhidrosis Pipeline Report
• DelveInsight's Axillary Hyperhidrosis Pipeline analysis depicts the space with 3+ active players working to develop 3+ pipeline therapies.
• The leading Axillary Hyperhidrosis Companies includes GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical, and others.
• Promising Axillary Hyperhidrosis Pipeline Therapies includes WO3979, WO3992, Sofpironium Bromide, 15%, Sofpironium Bromide, 15%, WO3970, ANT-1403, Vaser, and others.
• The Axillary Hyperhidrosis companies and academics are working to assess challenges and seek opportunities that could influence Axillary Hyperhidrosis R&D. The Axillary Hyperhidrosis pipeline therapies under development are focused on novel approaches to treat/improve Axillary Hyperhidrosis.
Explore more information on the latest breakthroughs in the Axillary Hyperhidrosis treatment landscape of the report and Axillary Hyperhidrosis Pipeline Outlook @ https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Axillary Hyperhidrosis Overview
Hyperhidrosis is a medical condition that causes excessive sweating. The word "hyperhidrosis" (hi-purr-hi-DROE-sis) means too much (hyper) sweating (hidrosis). Primary hyperhidrosis is a rare disorder characterized by excessive sweating on the palms of the hands, the soles of the feet, in the armpits (axillary), in the groin area, and/or under the breasts. The etiology of axillary hyperhidrosis is unknown but is related to increased cholinergic sympathetic stimulation of the sweat glands in the axilla. Although the glands invariably become remarkably hypertrophied in this condition, the dramatic glandular growth and oversecretion is believed to be secondary rather than primary The symptoms of primary hyperhidrosis typically begin during childhood or puberty and may often, although not always, persist throughout a person's life.
Axillary Hyperhidrosis Emerging Drugs Profile
• Sofpironium bromide: Brickell Biotech Inc.
Sofpironium bromide is a new chemical entity that we are currently developing in the U.S. as a potential best-in-class, self-administered, once-daily, topical therapy for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating. The drug is a retro metabolically designed anticholinergic agent which selectively binds to M3 AC receptor potentially inhibiting sweat production.
• ET-01: Eirion Therapeutics
ET-01 is a topical botulinum product being developed with the goal of avoiding the pain, bleeding and bruising that can be associated with the injection of commercially available botulinum products. ET-01 employs a nanoemulsion transdermal delivery technology essential for a large molecule such as botulinum to penetrate into the skin.The drug is currently being developed in Phase 2 stage of development for the treatment of Axillary Hyperhidrosis.
• DMT410: Dermata Therapeutics LLC pipeline
DMT410 is the second development program using DMT400 combination regimen in combination with botulinum toxin. Dermata Therapeutics have completed a proof of concept, Phase 1 clinical trial using DMT410 in combination with BOTOX® for the treatment of primary axillary hyperhidrosis. The treatment was well tolerated, and a majority of patients saw a reduction in sweat production similar to results seen from using injections of BOTOX®.
Request a sample and discover the recent advances in Axillary Hyperhidrosis Pipeline Therapies, visit Axillary Hyperhidrosis Treatment Landscape @ https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Axillary Hyperhidrosis Pipeline Therapeutics Assessment
There are approx. 3+ key companies which are developing the therapies for Axillary Hyperhidrosis. The companies which have their Axillary Hyperhidrosis drug candidates in the most advanced stage, i.e. phase III include, Brickell Biotech Inc.
Axillary Hyperhidrosis Pipeline Segmentation
Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Get to know more information about the Axillary Hyperhidrosis Emerging Drugs and Axillary Hyperhidrosis Companies of the report @ https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Axillary Hyperhidrosis Pipeline Report
• Coverage- Global
• Axillary Hyperhidrosis Companies- GlaxoSmithKline, Medytox, Theravida, Candesant Biomedical, and others.
• Axillary Hyperhidrosis Pipeline Therapies- WO3979, WO3992, Sofpironium Bromide, 15%, Sofpironium Bromide, 15%, WO3970, ANT-1403, Vaser, and others.
• Axillary Hyperhidrosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action
Dive deep into rich insights for drugs for Axillary Hyperhidrosis Market Drivers and Axillary Hyperhidrosis Market Barriers, click here Axillary Hyperhidrosis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Axillary Hyperhidrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Axillary Hyperhidrosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Sofpironium bromide: Brickell Biotech Inc
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. ET-01: Eirion Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Axillary Hyperhidrosis Key Companies
21. Axillary Hyperhidrosis Key Products
22. Axillary Hyperhidrosis - Unmet Needs
23. Axillary Hyperhidrosis - Market Drivers and Barriers
24. Axillary Hyperhidrosis - Future Perspectives and Conclusion
25. Axillary Hyperhidrosis Analyst Views
26. Axillary Hyperhidrosis Key Companies
27. Appendix
Got Queries? Find out the related information on Axillary Hyperhidrosis Mergers and acquisitions, Axillary Hyperhidrosis Licensing Activities, and Click here for Axillary Hyperhidrosis Emerging Drugs, and Recent Trends @ https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Axillary Hyperhidrosis Pipeline Appears Robust With 3+ Key Pharma Companies Actively Working in the Therapeutics Segment here
News-ID: 2961829 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Hyperhidrosis
Hyperhidrosis Market Massive Growth opportunity Ahead
Introduction
Hyperhidrosis, a condition characterized by excessive sweating beyond physiological needs, affects millions of people worldwide. It often impacts quality of life, causing emotional distress, social withdrawal, and occupational challenges. Primary hyperhidrosis typically involves localized sweating in areas like the palms, soles, and underarms, while secondary hyperhidrosis is linked to systemic conditions or medications.
The global hyperhidrosis market has been gaining traction due to rising awareness, increasing diagnosis rates, and advancements in…
Major Growth Driver Identified in 2025 Hyperhidrosis Treatment Market: Rising Pr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
Hyperhidrosis Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for hyperhidrosis treatment has significantly expanded in the latter years. It's projected to rise from $1.58 billion in 2024 to $1.67 billion in 2025, showcasing a compound annual growth rate (CAGR) of…
Rising Prevalence Of Diabetes Mellitus Boosts The Hyperhidrosis Treatment Market …
The Hyperhidrosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Hyperhidrosis Treatment Market Size During the Forecast Period?
The market size for hyperhidrosis treatment has seen significant growth in recent years. The market value is predicted to increase from $1.58 billion…
Leading Element Driving Change in the Hyperhidrosis Treatment Market in 2025: Ri …
What combination of drivers is leading to accelerated growth in the hyperhidrosis treatment market?
The hyperhidrosis treatment market is likely to be driven by the growing incidence of diabetes mellitus, a health condition that arises when the body fails to produce sufficient insulin or fails to respond to insulin appropriately, leading to abnormally high blood sugar levels. Diabetes tends to damage the nerves that control sweat glands, resulting in excessive sweating…
Major Market Shift in Hyperhidrosis Treatment Industry: Introduction Of Wipe For …
What Is the Forecasted Market Size and Growth Rate for the Hyperhidrosis Treatment Market?
The hyperhidrosis treatment market is projected to grow from $1.58 billion in 2024 to $1.67 billion in 2025, at a CAGR of 5.9%. The growth is driven by increasing awareness of the psychosocial impact of hyperhidrosis, cosmetic concerns, and regulatory support.
The Hyperhidrosis Treatment market is projected to grow to $2.13 billion by 2029 at a CAGR of…
Hyperhidrosis Treatment Market Segmentation and Analysis Report, 2027
Transparency Market Research (TMR) has published a new report on the global hyperhidrosis treatment market for the forecast period of 2019-2027.
According to the report, the global hyperhidrosis treatment market was valued at ~US$ 1.2 Bn in 2018, and is projected to expand at a CAGR of ~4% from 2019 to 2027. The global market is driven by increase in awareness and acceptance of hyperhidrosis treatment due to the launch of…
